Raleigh Capital Management Inc. Sells 3,794 Shares of AbbVie Inc. $ABBV

Raleigh Capital Management Inc. lessened its position in AbbVie Inc. (NYSE:ABBV) by 21.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,297 shares of the company’s stock after selling 3,794 shares during the quarter. AbbVie makes up about 1.2% of Raleigh Capital Management Inc.’s holdings, making the stock its 12th biggest holding. Raleigh Capital Management Inc.’s holdings in AbbVie were worth $3,740,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Burk Holdings LLC acquired a new stake in AbbVie during the 2nd quarter valued at $30,000. Marquette Asset Management LLC lifted its holdings in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Principia Wealth Advisory LLC lifted its holdings in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. IMG Wealth Management Inc. boosted its position in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after buying an additional 153 shares during the period. Finally, Tacita Capital Inc acquired a new stake in shares of AbbVie in the second quarter worth $42,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their price target on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. Rothschild & Co Redburn increased their price objective on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Guggenheim reissued a “buy” rating and issued a $288.00 price objective on shares of AbbVie in a research note on Friday, October 9th. Royal Bank Of Canada restated an “outperform” rating and set a $280.00 price objective on shares of AbbVie in a research report on Tuesday, October 13th. Finally, Barclays lifted their target price on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $279.86.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Trading Up 1.4%

Shares of NYSE:ABBV opened at $294.80 on Friday. The firm has a market cap of $520.85 billion, a price-to-earnings ratio of 83.28, a P/E/G ratio of 1.33 and a beta of 0.24. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $298.74. The business has a fifty day simple moving average of $269.35 and a 200 day simple moving average of $237.23.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the previous year, the company posted $1.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts forecast that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.